.Pharmacolibrary.Drugs.ATC.J.J07BN01 .Pharmacolibrary.Drugs.ATC.J.J07BN01| name: | Covid19RnaBasedVaccine | |
| ATC code: | J07BN01 | |
| route: | intramuscular | |
| compartments: | 1 | |
| dosage: | 30 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | liter/hour |
| other parameters in model implementation | ||
COVID-19, RNA-based vaccines (such as those developed by Pfizer/BioNTech and Moderna) are mRNA vaccines that instruct cells to produce the SARS-CoV-2 spike protein, which induces an immune response. These vaccines are approved and widely used globally for the prevention of COVID-19.
Estimated pharmacokinetic parameters for healthy adult individuals; published literature does not report standard PK values for mRNA vaccines due to their mechanism of action and rapid degradation.